Advanced Metastatic Head and Neck Squamous Cell Carcinoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

It is unknown where squamous cell cancer first develops in the body, but in metastatic squamous cell cancer of the neck, the disease has spread to the neck's lymph nodes. Anywhere in the body, squamous cells have the potential to develop into cancer, which then has the ability to spread (metastasize) to other body parts via the lymphatic or blood systems. The epidemiology of head and neck squamous cell carcinomas (HNSCC) has changed significantly over the past 50 years as cancers brought on by the human papillomavirus (HPV) are becoming more common and HNSCCs caused by smoking are becoming less frequent. Cisplatin, carboplatin, and antitubular substances like taxanes, phenalkaloids, and fluoropyrimidines are among the substances that have been demonstrated to be effective. Platinum in combination with a taxane or fluorouracil produced a response rate of 30% and a median overall survival of 6 to 8 months in disease and metastases that were resistant to treatment.

Description

It is unknown where squamous cell cancer first develops in the body, and in metastatic squamous cell cancer of the neck, the cancer has spread to the neck's lymph nodes. Cancer can begin in squamous cells anywhere in the body and spread (metastasize) to other body parts via the lymphatic or blood system. Squamous cell carcinoma of the neck is referred to as metastatic squamous cell carcinoma of the neck when it spreads to the lymph nodes near the neck or collarbone. The mucosa of the upper gastrointestinal tract gives rise to the heterogeneous disease known as head and neck squamous cell carcinoma (HNSCC). Despite receiving multimodality therapy, the prognosis is poor for 50% of patients who have locally advanced disease recurrence or HNSCC that has spread to other parts of their bodies.

Advanced Metastatic Head and Neck Squamous Cell Carcinoma (Epidemiology)

The epidemiology of head and neck squamous cell carcinomas (HNSCC) has changed significantly over the past 50 years, with a significant increase in cancers caused by the human papillomavirus (HPV) and a significant decline in HNSCCs caused by smoking. The shift in HNSCC risk factors has affected the distribution of the affected anatomical subsites, patient demographics, and the prognosis of this condition. Every year, more than 550,000 patients are given the disease's diagnosis worldwide. More than 380,000 people were killed. Lip and oral cancer are the 15th and 10th most prevalent cancers globally, respectively, and in South and Southeast Asia, tropical Latin America, and sub-Saharan Africa. This information comes from the Global Burden of Disease Study. The incidence has risen by 36.5% over the last ten years. The 20th most prevalent cancer, neck cancer, has increased by 23.1% over the previous ten years. Having increased by 29.9%, mouth and throat cancer was the 24th most common cancer.

Advanced Metastatic Head and Neck Squamous Cell Carcinoma -Current Market Size & Forecast Trends

The market for advanced metastatic head and neck squamous cell carcinoma (HNSCC) is projected to grow significantly, with estimates indicating a value of approximately USD 1.0 billion in 2023. It is expected to reach around USD 2.4 billion by 2034, reflecting a compound annual growth rate (CAGR) of 8.16% during this period due to the increasing adoption of targeted therapies and immunotherapies, such as EGFR inhibitors and checkpoint inhibitors like pembrolizumab and nivolumab. Additionally, the global head and neck cancer therapeutics market, which includes HNSCC, was valued at approximately USD 2.04 billion in 2023 and is projected to grow at a CAGR of 11.8% through 2030, driven by rising incidence rates and advancements in treatment options. The market is primarily fueled by the increasing prevalence of head and neck cancers, particularly associated with risk factors such as tobacco use, alcohol consumption, and HPV infections. Overall, the advanced metastatic HNSCC market is well-positioned for substantial growth through 2035 as new therapies and treatment strategies continue to emerge.

Antitubular substances like taxanes, phenalkaloids, and fluoropyrimidines, as well as the chemotherapy drugs cisplatin and carboplatin, have all been demonstrated to be effective. Combination therapy with platinum and a taxane or fluorouracil produced a response rate of 30% and a median overall survival of 6 to 8 months in disease and metastases that were resistant to treatment. Response rates to the three new chemotherapy regimens were between 40 and 50%, and overall survival did not significantly improve. The treatment of various malignancies has recently shifted to a new class of medications that target signaling pathways. Because the intracellular kinase domain of the receptor is frequently expressed in SCCHN and plays a role in promoting cell growth and proliferation, molecules that target this region make sense. When used separately, gefitinib and erlotinib had response rates between 5 and 15%. Clinical trials are also being conducted to develop novel medications with broad-spectrum activity against EGFR and other related erbB receptor family members. Investigate methods to boost the efficacy of EGFR tyrosine kinase inhibitors (TKIs) in SCCHN therapy and identify tumor types most likely to respond to these medications. This article reviews therapeutic advancements in the management of drug-resistant and metastatic disease with a special emphasis on the difficulties of successfully integrating EGFR inhibition into therapeutic models of SCCHN tumors. Most patients with locally advanced head and neck squamous cell carcinoma (HNSCC) will experience relapse. Relapsed/metastatic (R/M) HNSCC patients are now treated with a variety of methods. Topics covered: A thorough overview of the most recent systemic therapies for R/M HNSCC will be given in this article. Expert opinion: For patients with R/M HNSCC who have not yet received chemotherapy, EXTREME (cetuximab plus platinum and 5-fluorouracil) continues to be the gold standard of care. Methotrexate, cisplatin, 5-FU, docetaxel, and paclitaxel are examples of specific medications with well-established activity in HNSCC. The anti-PD-1 monoclonal antibody nivolumab can be regarded as the current gold standard of treatment for patients with advanced R/M HNSCC following platinum therapy, per the findings of CheckMate 141. Weekly cetuximab, methotrexate, or docetaxel, PD-1 monoclonal antibody. Anti-PD(L) antibodies and EXTREME have been compared in a number of randomized phase III trials, either as a single agent or in continuous or scheduled team therapy with chemotherapy or anti-CTLA-4 lines. The findings of these studies could alter how R/M HNSCC is currently being treated.

Report Highlights

Advanced Metastatic Head and Neck Squamous Cell Carcinoma - Current Market Trends

Advanced Metastatic Head and Neck Squamous Cell Carcinoma - Current & Forecasted Cases across the G8 Countries

Advanced Metastatic Head and Neck Squamous Cell Carcinoma - Market Opportunities and Sales Potential for Agents

Advanced Metastatic Head and Neck Squamous Cell Carcinoma - Patient-based Market Forecast to 2035

Advanced Metastatic Head and Neck Squamous Cell Carcinoma - Untapped Business Opportunities

Advanced Metastatic Head and Neck Squamous Cell Carcinoma - Product Positioning Vis-a-vis Competitors' Products

Advanced Metastatic Head and Neck Squamous Cell Carcinoma - KOLs Insight